Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02700841 · ClinicalTrials.gov registry record · Phase 2
Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
A Phase 2 study, sponsored by University of Nebraska.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT02700841: Clinical Trial Phase 2 study, sponsored by University of Nebraska.
NCT02700841 is a Phase 2 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02700841, a Phase 2 study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This pilot randomized Phase II trial (10 subjects per arm) will compare immune reconstitution following transplantation of an autologous mobilized graft product to reconstitution following transplantation of a mobilized graft product followed by an autologous lymphocyte infusion collected prior to G-CSF mobilization. All subjects will receive tetanus vaccines pre and post-transplant. The primary end point will be tetanus vaccine immune responses post-transplant.
Primary Outcome
Determine safety of outcomes based on the number of safely treated participants by CTCAE version 5.0 tool
Interventions
- DRUG Melphalan
- BIOLOGICAL T Cell-Depleted Hematopoietic Stem Cell Transplantation
- BIOLOGICAL Tetanus Toxoid Vaccine
- PROCEDURE Peripheral Blood Stem Cell Transplantation--CD34 HSCT
- PROCEDURE Peripheral Blood Stem Cell Transplantation--AHSCT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-01-09 |
| Est. Completion | 2022-12-21 |
| Phase | Phase 2 |
Why NCT02700841 stopped before completion
NCT02700841 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT02700841 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02700841 about?
NCT02700841 is a clinical study titled "Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation". This pilot randomized Phase II trial (10 subjects per arm) will compare immune reconstitution following transplantation of an autologous mobilized graft product to reconstitution following transplantation of a mobilized graft product followed by an autologous lymphocyte infusion collected prior to G...
What is the current status of trial NCT02700841?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2020-01-09. Estimated completion is 2022-12-21.
What interventions are being tested in trial NCT02700841?
The interventions under investigation include: Melphalan (DRUG), T Cell-Depleted Hematopoietic Stem Cell Transplantation (BIOLOGICAL), Tetanus Toxoid Vaccine (BIOLOGICAL), Peripheral Blood Stem Cell Transplantation--CD34 HSCT (PROCEDURE), Peripheral Blood Stem Cell Transplantation--AHSCT (PROCEDURE).
Who is sponsoring clinical trial NCT02700841?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02700841's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI